PCOS Has a New Name. Your Diagnosis Doesn't — Yet.

For decades, doctors named a common hormonal condition after something that, for most patients, was never actually there. In May 2026, an international coalition of researchers finally said so out loud and gave polycystic ovary syndrome a new name. The insurance form at your next appointment will probably still say the old one.

What's actually true: In May 2026, a fourteen-year global consensus involving 56 patient and professional organizations, published in The Lancet, formally renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) — recognizing that the ovarian “cysts” were never the condition's defining feature, and that it is a body-wide hormonal and metabolic disorder. What's misleading or unregulated: The name is official. The paperwork is not. Diagnostic criteria, insurance codes, medical records, and most prescriptions will keep saying PCOS for years — full guideline implementation isn't scheduled until 2028 — and the deeper question of which patients actually meet the definition was never settled to begin with.

The “cysts” in polycystic ovary syndrome were never much of a diagnostic anchor to begin with. The condition affects roughly one in eight women worldwide — more than 170 million people — and for close to a century it has carried a name built on a misreading. About a hundred years ago, surgeons who noticed small sac-like structures on a patient's ovaries assumed they were looking at cysts, and the diagnosis got built around that assumption. But those structures are arrested ovarian follicles, not pathological cysts, and a companion paper from the same research group behind the renaming found no increase in abnormal ovarian cysts in women with the condition at all.

That gap between the name and the biology finally got an official correction. On May 12, 2026, The Lancet published the result of a multistep global consensus process that had been underway for fourteen years: more than 22,000 survey responses, workshops on several continents, and 56 patient and professional organizations — including the Endocrine Society and the American Society for Reproductive Medicine — signing on to a new name. Polycystic ovary syndrome is now polyendocrine metabolic ovarian syndrome, or PMOS.

Helena Teede, the Monash University endocrinologist who led the process, put it plainly: there is no increase in abnormal cysts on the ovary, and the condition's other features — the ones that actually drive long-term health risk — had gone unappreciated for decades. Those features are hormonal and metabolic, not anatomical. Insulin resistance. Elevated androgens. Long-term risk of type 2 diabetes and cardiovascular disease. Menstrual irregularity is one symptom among several, not the whole story.

Lubna Pal, a reproductive endocrinologist at Yale Medicine who contributed patient survey data to the renaming effort, describes the shift as moving from a “microscopic” view of the condition to a “telescopic” one. The old name pointed a magnifying glass at the ovary. The new one is supposed to widen the frame to the whole endocrine system — weight, skin, mood, metabolism, fertility — all at once. She compares the condition to a hand-wound watch: turn one cog and a ripple of motion runs through all the others. The clinical task, she says, is figuring out which cog is actually driving the dysfunction in a given patient, not just re-winding the watch.

Here's what the new name does not touch: which patients get the diagnosis in the first place. That question has been unsettled since long before PMOS existed. Clinicians currently lean on the 2003 Rotterdam criteria, which flag the condition if a patient has two of three features — irregular ovulation, signs of excess androgen, or polycystic-appearing ovaries on ultrasound. That's a looser net than the 1990 NIH criteria it replaced, and looser still than the 2006 criteria proposed by the Androgen Excess Society. Run the same patient population through each rulebook and the diagnosis rate swings wildly: one comparative study found roughly 26 percent of women qualified under the NIH criteria, 29 percent under the Androgen Excess Society's, and 63 percent under Rotterdam's — for the identical group of patients. One physician called the broader Rotterdam expansion premature back in 2006, and the argument was never fully resolved. PMOS inherits that argument intact.

So what should someone with an existing PCOS diagnosis actually do with this news? Nothing urgent. Pal is direct about it: your diagnosis remains valid, and you don't need to ask your doctor to relabel your chart. But the rename is a reasonable prompt to bring a few concrete questions to your next appointment, since it's aimed squarely at a blind spot in how this condition tends to get followed over time.

• Has anyone checked my fasting glucose, insulin, or HbA1c recently — not just my hormone panel?
• What does my cholesterol and cardiovascular risk profile look like, independent of whether I'm trying to get pregnant right now?
• My periods have become more regular — does that mean the underlying condition has improved, or just that one symptom has quieted down?
• Should I be seeing an endocrinologist alongside my gynecologist for the metabolic side of this, not just the reproductive side?

That's the exact blind spot the rename is trying to close: patients whose reproductive symptoms fade off the radar while their metabolic risk keeps building quietly in the background. Asking those four questions costs nothing and doesn't require the new name to have reached your clinic yet.

Expect a lag everywhere else. Insurance claims, prescription labels, and most electronic health records will keep running on PCOS for the foreseeable future, and the international clinical guideline that actually governs diagnosis and treatment isn't due for its next update until 2028 — the point at which PMOS gets folded in formally. Until then, both names will circulate side by side, and a patient could reasonably see PCOS on a lab requisition and PMOS in a doctor's note about the exact same visit.

The consumer-facing version of the old name has its own momentum, too. Search “polycystic ovary” on social platforms and a good chunk of what surfaces is built entirely around the discarded premise — supplements marketed to “shrink” or “detox” ovarian cysts, content that treats the ultrasound finding as the disease itself. That marketing didn't misread the science by much more than the original 1920s surgeons did; it just kept selling the misreading decades after clinicians started to move past it. A name change from a medical journal doesn't reach a For You page automatically, and nothing about PMOS stops a supplement label from putting “cyst support” on the front of the bottle next month.

The name changed. The paperwork, the diagnostic criteria, and the marketing didn't — not yet, and not automatically. Whether calling it PMOS actually shortens the diagnostic delay that currently leaves an estimated 70 percent of cases unrecognized is a bet the consensus authors are making, not a result anyone has measured. That's the honest state of the evidence right now: a real, well-documented decision about language, resting on a hypothesis about behavior that the 2028 guideline cycle will be the first real test of. In the meantime, the most useful thing a patient can do is ask their own doctor those four questions directly, rather than wait for a new acronym to show up on a chart.

Related: The Estrogen Reversal

1. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet, 2026. thelancet.com
2. Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide. Endocrine Society, press release, May 12, 2026. endocrine.org
3. PCOS is Now PMOS: Understanding the Name Change. American Society for Reproductive Medicine, 2026. asrm.org
4. Macmillan, C. PCOS Is Renamed PMOS: What You Need to Know. Yale Medicine, June 23, 2026. yalemedicine.org
5. Azziz, R. Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature. Journal of Clinical Endocrinology & Metabolism, 2006. academic.oup.com
6. Polycystic Ovary Syndrome: Pathophysiology and Controversies in Diagnosis. PMC / National Library of Medicine, 2023. ncbi.nlm.nih.gov
7. PCOS gets a new name: PMOS. CNN, May 13, 2026. cnn.com

Disclaimer: This content includes personal opinions and interpretations based on available sources and should not replace medical advice. This content includes interpretation of available research and should not replace medical advice. Although the data found in this blog and infographic has been produced and processed from sources believed to be reliable, no warranty expressed or implied can be made regarding the accuracy, completeness, legality or reliability of any such information. This disclaimer applies to any uses of the information whether isolated or aggregate uses thereof.